METTL2B Antibody

Oncogenic Role in Ovarian Cancer

• METTL2B expression is significantly elevated in OC tissues compared to normal ovarian tissue, with an AUC of 0.801 for diagnostic accuracy .

• High METTL2B expression correlates with poor progression-free survival (PFS) and immune microenvironment disruption .

• Knockdown of METTL2B inhibits OC cell proliferation, migration, and invasion by suppressing the AKT/mTOR signaling pathway .

Immune Microenvironment Modulation

• METTL2B negatively correlates with immune cell infiltration (e.g., cytotoxic T cells, NK cells) in the tumor microenvironment, suggesting immunosuppressive effects .

Drug Sensitivity

• Patients with high METTL2B expression exhibit increased sensitivity to chemotherapeutic agents, positioning METTL2B as a potential therapeutic target .

4. Experimental Validation
The antibody’s specificity and efficacy are demonstrated in:

5. Clinical Implications
The METTL2B antibody has diagnostic and prognostic potential in ovarian cancer. Its ability to detect METTL2B overexpression aligns with emerging evidence linking m3C modifications to cancer progression . Future studies may explore its utility in monitoring treatment response or identifying therapeutic targets .